Asset profile
Rina-S
Small molecule
Evidence outlook · registrational
Ovarian Cancer: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2028-10.
Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 1/2Non-Small Cell Lung Cancer · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
128 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 127 same-indication; 86 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Rina-S: this drug | Phase 3 | Small molecule | Folate receptor alpha (FRα) | ||
| LY4170156 | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| Avutometinib | Approved | Small molecule | RAF/MEK, MEK1/2 and RAF (CRAF, BRAF) | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 |
…and 113 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (3)
July 2027 (1)
What to watch
September 2027 (1)
What to watch
November 2027 (1)
What to watch
2028 (2)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.